Six Wall Street Analysts on What's Next for the Sarepta Duchenne Drug Story

Sarepta Therapeutics and its backers endured an emotional FDA advisory committee meeting yesterday for eteplirsen, its Duchenne Muscular Dystrophy drug. The Cambridge, Mass.-based company failed to win the expert recommendation it was seeking, as the FDA panel voted 7-3 against allowing its new drug on the U.S. market for boys with this crippling, and deadly, genetic disease.